Related by context. All words. (Click for frequent words.) 68 SUCCEED trial 67 randomized controlled Phase 67 STRIDE PD 67 Phase Ib II 67 ACCEDE 66 Phase III ADT 66 Phase IIb III 65 NO# [002] 65 BRIM3 65 Randomized Phase II 65 phase III ACCLAIM 65 Phase IIIb clinical 65 TG MV 65 multicenter Phase II 65 ENDEAVOR IV 65 PROTECT AF 65 LUX Lung 65 APEX PD 65 Phase Ib clinical 64 ICON7 64 confirmatory clinical 64 ToGA 64 ENDEAVOR III 64 Phase III ThermoDox 64 BCIRG 64 including eniluracil ADH 63 Prostate AdenoCarcinoma Treatment 63 Bayer HealthCare Onyx Pharmaceuticals 63 phase IIb clinical 63 BRIM2 63 rALLy clinical trial 63 ABSORB clinical 63 PANVAC VF 63 Phase #b/#a clinical 63 randomized Phase 2b 63 PRESEPT 63 Phase III Pivotal 63 IMA# 63 multicenter phase 63 CHAMPION PCI 63 Combination REOLYSIN R 63 hGH CTP Phase 63 phase IIa clinical 63 ELACYT 63 CURRENT OASIS 7 62 recombinant PSMA vaccine 62 Multicenter Phase 62 ADVANCE PD 62 AVOREN 62 oral ridaforolimus 62 fidaxomicin Phase 62 metastatic hormone refractory 62 EchoCRT 62 initiated Phase Ib 62 TEMSO 62 IMPACT DCM 62 HORIZONS AMI 62 Phase Ib IIa 62 assessing T DM1 62 multicenter Phase 62 ALN VSP Phase 62 GENASIS 62 PSMA ADC 62 Phase 2b RESTORE CLI 62 ENGAGE AF TIMI 62 SPIRIT IV 62 pharmacogenomic translational research 62 PRIMO CABG 62 multicenter randomized Phase 62 randomized controlled multicenter 62 Second Pivotal Phase 62 placebo controlled Phase III 61 GetGoal Phase III 61 solid tumors ZYBRESTAT 61 phase IIb trial 61 evaluating T DM1 61 pivotal bioequivalence 61 Phase 1b clinical trials 61 EMPOWER ™ 61 Phase lll 61 Initiated Phase 61 candidate CRLX# 61 Hepatocellular Carcinoma HCC 61 Phase 1a clinical 61 Telatinib 61 Renal Cell Carcinoma RCC 61 Diabetic Macular Edema 61 ADMIRE HF 61 Phase #/#a 61 initiate multicenter 61 MIST II 61 multicenter randomized controlled 61 riociguat 61 RE LY ® 61 CLIRS trial 61 Commences Phase 61 PROLARIS 61 registrational Phase 61 EVEREST II 61 evaluating Actimmune 61 Completes Patient Enrollment 61 OLYMPIA registry 61 CARE HF 61 Advaxis Phase 61 Initiates Enrollment 61 XL# SAR# 61 oral deforolimus 61 IMPACT IMmunotherapy 61 Val HeFT 61 Phase IIA 61 Refractory Angina 61 Phase III HEAT 61 MAGE A3 ASCI 61 Zemplar Capsules 60 Achieves Primary Endpoint 60 Initiates Phase II 60 PRIMO CABG2 60 Phase 2b kidney transplant 60 Phase III VISTA 60 rALLy 60 Phase Ib study 60 comparing XIENCE V 60 phase IIb study 60 AEG# 60 LUMINATE 60 PARTNER Trial 60 ABSORB trial 60 dose escalation phase 60 Randomized Phase III 60 budesonide foam 60 NSABP B 60 placebo controlled multicenter 60 alvespimycin 60 Pivotal Phase 60 Randomized Phase 60 Prednisone Against Refractory 60 Phase IIB 60 tesmilifene 60 generation PNP inhibitor 60 randomized Phase IIb 60 CINQUIL 60 multicenter randomized placebo controlled 60 CA9 SCAN 60 Pivotal Clinical Trial 60 Matrix Phase 2b 60 AVN# Phase 60 ANCHOR trial 60 STEALTH C 60 Initiate Phase 60 deCODE ProstateCancer TM 60 phase IIa 60 Relapsing Remitting MS 60 HDL Selective Delipidation 60 Phase III AFFIRM 60 Harry Palmin President 60 Charles L. Dimmler 60 doxorubicin Transdrug ® 60 RECORD1 60 SPIRIT FIRST 60 Prospective Randomized 60 SYMMETRY trial 60 mg/m2 cohort 60 relapsing remitting MS RRMS 60 treatment naive genotype 60 Initiates Phase III 60 MEND CABG 60 recurrent malignant glioma 60 landmark ATHENA 60 tramiprosate Alzhemed TM 60 Randomized Evaluation 60 SUTENT ® 60 Oncotype DX colon cancer 60 confirmatory Phase 59 recurrent metastatic ovarian cancer 59 EMPHASIS HF trial 59 Empatic ™ 59 Multicenter Automatic Defibrillator Implantation 59 CURE AF 59 phase IIb 59 PD2i CA Cardiac Analyzer 59 Randomized controlled 59 BrachySil TM 59 ACCORD Lipid 59 successfully commercialize Iluvien 59 REVEAL Registry 59 ENESTnd 59 apricitabine ATC 59 phase Ib 59 Huggins Cams Time 59 BST CarGel R 59 ENDEAVOR II 59 elotuzumab 59 ENABLE Phase 2 59 GENASIS clinical 59 Successfully Completes Phase 59 Cloretazine ® 59 HuCAL antibodies 59 eTag assays 59 Meets Primary Endpoint 59 initiated Phase 1b 59 TASKi3 59 biliary tract cancer 59 RE LY 59 fidaxomicin Phase 3 59 ROCKET AF 59 TNFerade TM 59 EXPLORE Xa 59 ATIR ™ 59 Ovarian Cancer Screening 59 REMINYL ® 59 metastatic pancreatic 59 novel VDA molecule 59 rALLy trial 59 REVIVE TA 59 Acute Decompensated Heart Failure 59 Ophena 59 forodesine 59 OvaRex R 59 COSIRA trial 59 Pivotal Phase II 59 paclitaxel poliglumex 59 multicenter multinational 59 multicenter prospective 59 evaluating satraplatin plus 59 StudyOptimizer 59 Randomized phase 59 NEVO RES 59 Multicenter Randomized 59 placebo controlled Phase 59 CLIRS 59 LibiGel Phase III 59 ThermoDox ® clinical 59 oral FTY# 59 PRESEPT study 59 multicenter randomized clinical 59 AIMM trial 59 visit http:/www.clinicaltrials.gov/ 59 Thorough QT 59 initiate Phase 1b 59 First Patient Enrolled 59 Gentamicin Surgical Implant 59 IMC #B 59 HCV SPRINT 59 ExTRACT TIMI 59 metastatic renal cell 59 Phase 1b trial 59 Tesmilifene 59 Tykerb lapatinib 59 deCODE AF TM 59 GENASIS trial 59 leading oral taxane 59 CVac 59 Degarelix 59 reduce serum phosphate 59 targeting miR 59 TAXUS IV 59 bapineuzumab AAB 58 Carotid Stenting 58 PFO migraine 58 metastatic sarcomas 58 PathFinderTG 58 p# biomarker 58 Trofex 58 MKC# MKC# PP 58 multicentre randomized 58 PF # [002] 58 CLARITY study 58 deforolimus 58 REALITY Trial 58 Phase III Psoriasis 58 Colorectal Cancer CRC 58 CYT# potent vascular disrupting 58 comparing alemtuzumab 58 randomized multicentre 58 Phase 2b Clinical Trial 58 unresectable stage 58 BiovaxID Phase 58 EDEMA3 58 Novo TTF 58 LHRH receptor positive 58 Hormone Refractory Prostate Cancer 58 Phase IIIb 58 Patient Enrollment 58 AVADO 58 evaluating tivozanib 58 placebo controlled randomized 58 Myocet 58 Tovaxin Phase IIb 58 Phase III Clinical Trial 58 Dose Escalation 58 Tumor Response 58 OnDose TM 58 BARI 2D 58 OPT CHF 58 Elocalcitol 58 CCX# 58 metaglidasen 58 Phase III randomized controlled 58 Phase III randomized 58 prospectively defined 58 RIO Lipids 58 AFRS TM 58 QUASAR validation study 58 sapacitabine CYC# 58 multicenter randomized Phase III 58 phase III SIMPADICO 58 Advanced Melanoma 58 Maximum Tolerated Dose MTD 58 number NCT# ClinicalTrials.gov 58 XIENCE V Stent System 58 evaluating mipomersen 58 ongoing Phase 1b 58 Recurrent Glioblastoma 58 MEND CABG II 58 Trastuzumab DM1 58 StemEx R 58 trastuzumab DM1 T DM1 58 evaluating intravenous picoplatin 58 Phase 2b study 58 ADVANCE ILLUMINATE 58 isavuconazole 58 Elagolix 58 Initiate Phase II 58 PERSEUS 58 R# #mg BID 58 HORIZONS AMI trial 58 Azedra 58 Breast Density 58 registrational 58 lorcaserin Phase 58 Demonstrates Sustained 58 CRMD# 58 signal detection CTSD 58 Panzem R NCD 58 Oral Calcitonin 58 opioid induced bowel dysfunction 58 Oral Fingolimod 58 Prostate Cancer Prevention 58 Delcath Phase III 58 ONTARGET 58 LungAlert TM 58 lintuzumab SGN 58 CALGB 58 Medidur TM FA 58 APEX AMI 58 Albuferon Phase 58 Zenvia ™ 58 imetelstat GRN#L 58 phase IIIb 58 prospective randomized placebo 58 PDE# inhibitors 58 Glufosfamide 58 CEL SCI Phase III 58 Topline Results 58 ThermoDox R 58 NABTT 58 DATATRAK eClinical ™ 58 Ophena TM 58 trastuzumab emtansine T DM1 58 EndoTAGTM 1 58 TAXUS ATLAS 58 Motesanib 58 Phase IIb randomized 58 APF# Phase 58 evaluating Prochymal 58 controlled multicenter Phase 58 CAPACITY trials 58 unique alkylating agent 58 relapsed MM 58 trastuzumab DM1 58 Phase #b/#a 58 Testosterone MDTS ® 58 Allovectin 7 58 budesonide MMX Phase III 58 Cervical Dysplasia 58 Pivotal Trial 58 Phase IIb clinical 58 Custirsen 58 farletuzumab 58 Corgentin 58 European Sepsis Trial 57 PROMUS Element Stent 57 Outpatient Setting 57 Exherin TM 57 Phase 1b 57 Diamyd Medical Diamyd 57 Clinical Outcomes Utilizing Revascularization 57 Randomized Study 57 Proellex TM 57 Androxal TM 57 APEX AMI trial 57 GVAX ® 57 multicenter placebo controlled 57 Preclinical Models 57 Factor VIIa 57 Phase IIa trials 57 Cholesterol Levels SPARCL 57 pharmacodynamic effects 57 registrational trial 57 coronary stent merged 57 Phase Ia 57 SYNTAX trial 57 Octreolin 57 Initiate Phase III 57 Phase 1a 57 Pazopanib 57 Bezielle 57 pivotal Phase III 57 pharmacokinetic PK study 57 CTAP# Capsules 57 PERSEUS clinical program 57 Sorafenib HCC Assessment 57 Fabry Disease 57 randomized Phase III 57 multicentre prospective 57 metastatic HRPC 57 resectable pancreatic cancer 57 PLCO 57 Randomised 57 BRAF mutated 57 Phase III 57 HuMax TAC 57 Randomized Clinical Trial 57 prospectively stratified 57 HCV NS5B polymerase 57 recurrent NSCLC 57 zileuton IV 57 MADIT II 57 IMPACT DCM clinical 57 AIM HIGH 57 TASKi2 57 Randomized Double blind 57 CEQ# 57 benign prostatic hyperplasia enlarged 57 Trial Issue www.emagazine.com 57 secondary efficacy endpoint 57 Hsp# Inhibitor 57 TCGA Pilot Project 57 Vertebral Fractures 57 Cardiotoxicity 57 VITAL Trial 57 PRE SURGE 57 Severe Sepsis 57 vinorelbine tartrate 57 phase 2a 57 Allovectin 7 ® 57 ENRICH trial 57 Raloxifene STAR 57 Rheos System 57 MKC# MT 57 Phase III Clinical Trials 57 Synta Announces 57 Dupuytren Disease 57 dirucotide MBP# 57 dose escalation Phase 57 evaluating nimotuzumab 57 BLOOM Behavioral modification 57 JAK2 Inhibitor 57 Hedgehog Pathway Inhibitor 57 PROSTVAC ® 57 naïve HCV 57 Randomized Clinical Trials 57 CCR9 antagonist 57 Telik Announces 57 viral kinetic 57 mSEPT9 biomarker 57 NCIC CTG 57 KRN# 57 SinuNase ™ 57 HPTN 57 PHX# 57 Confirmatory Phase 57 Recurrent Breast Cancer 57 Novel Oral 57 EURIDIS 57 Edge STudy 57 CR# vcMMAE 57 PROSTVAC TM 57 Solazed 57 APPRAISE 57 CRLX# 57 Phase IIB clinical 57 Dialysis Outcomes 57 ACRIN 57 OvaRex ® MAb 57 randomized multicenter trial 57 EMPOWER Study 57 Renal Cancer 57 TransVax ™ 57 REG2 57 CHARM Added 57 PROVENGE sipuleucel T 57 initiated confirmatory Phase 57 Aflibercept 57 Abstract Accepted 57 SPEAR Study 57 teriflunomide 57 SIMPADICO 57 ONCONASE R 57 clazosentan 57 acyclovir Lauriad R 57 galiximab 57 evaluating satraplatin 57 zanolimumab 57 Daclizumab 57 Cologuard 57 Quinamed 57 EINSTEIN DVT 57 Safinamide 57 Orosi Mill project 57 metastatic CRC 57 First Patient Dosed 57 Adjuvant Treatment 57 resistant hormone refractory 57 ExCell study 57 TTF Therapy 57 Stereotactic Body Radiation Therapy 57 metastatic CRPC 57 AeroLEF TM 57 HGS ETR2 57 Multiple Ascending Dose 57 BrachySil ™ 57 Shows Promise Against 57 randomized controlled clinical 57 OVATURE trial 57 regorafenib 57 RSD# IV 57 drug figitumumab 57 Selective Electrochemical Tumor Ablation 57 RE MODEL 57 Perifosine KRX 57 Initiates Phase 2b 57 NSABP C 57 Solorel TM 57 PRECISE Trial 57 Amoxicillin PULSYS Phase III 57 PITX2 methylation 57 randomized discontinuation 57 ORAL Sync 57 Prospective Multicenter 57 AZX# Phase 57 eritoran 57 HGS ETR1 mapatumumab 57 neratinib 57 novel therapeutic antibodies 56 treatment naïve genotype 56 Celacade TM technology 56 Orazol 56 Dr. Pingpank 56 dose escalation clinical 56 PORxin TM platforms 56 sNDA submission 56 multicenter Phase III 56 ACUITY trial 56 PCI ExTRACT TIMI 56 CUSTOM III 56 Bexion 56 Archexin 56 Exelixis XL# 56 TMC# C# 56 delivery polymer matrix 56 sarcoma melanoma 56 Cerebril TM 56 Clinical Antipsychotic Trials 56 Raloxifene Evaluation MORE 56 Corlux 56 azilsartan medoxomil 56 Patient Accrual 56 Atypical Hemolytic Uremic Syndrome 56 reslizumab 56 HeFH 56 immatics 56 Completes Enrollment 56 Phase 1b dose escalation 56 multicenter clinical 56 Dyloject TM 56 Metastatic Melanoma 56 MYTHOS trial 56 Intervention Effectiveness 56 INS# [001] 56 InForm ITM 56 Troxatyl 56 evaluating tesamorelin 56 Phase IIb trials 56 Prodarsan R 56 mertansine 56 Truvada tablets 56 double blinded placebo 56 haematological cancers 56 Efficacy Results 56 multicentre randomized controlled 56 oral picoplatin 56 metastatic castration resistant 56 FOLFOX6 chemotherapy regimen 56 pertuzumab 56 CONQUER OB 56 EFAPROXYN 56 IIb clinical trial 56 null responder HCV 56 Trial PCPT 56 Urocidin TM 56 Ozarelix 56 Microplasmin 56 Acute Ischemic Stroke 56 Annamycin 56 PLK1 SNALP 56 Phase III psoriasis 56 Treatment Shows Promise 56 Adjuvant Breast Cancer 56 Gastrointestinal Stromal Tumors 56 VALOR trial 56 Dural Sealant 56 Stage IIB 56 bevirimat Study 56 Asentar 56 metastatic ocular 56 HYVET 56 Tesetaxel 56 ORAL Solo 56 Deforolimus 56 Syndax Pharmaceuticals Inc. 56 Silodosin 56 Tavocept 56 Intravenous CP 56 ganetespib 56 MGd 56 PLX STROKE targeting 56 metastatic colorectal 56 Phase 2b trial 56 LibiGel testosterone gel 56 CATIE AD 56 double blinded randomized 56 intravesical infusion therapy 56 Urocortin 2 56 Dose Ranging 56 Romidepsin 56 Kamada AAT 56 pain palliation 56 Demonstrates Positive 56 OVATURE 56 Phase III clinical 56 Gentium Announces 56 Proc Am Soc 56 Phase 2b 56 MoxDuo ® 56 elacytarabine 56 Sapacitabine 56 everolimus eluting stents 56 Bicifadine 56 ARISE Phase III 56 opioid naive 56 ASCEND HF 56 metastatic renal 56 hyperphenylalaninemia HPA due 56 Decompensated Heart Failure 56 Biomarker Study 56 Engage Analytics 56 Phase III multicenter 56 developed preclinically 56 Nasdaq MAPP 56 product TNFerade TM 56 TEC #OL 56 prospective multicentre 56 IRX 2 56 BLA filing 56 placebo controlled clinical 56 Initiates Clinical Trial 56 blinded randomized placebo controlled 56 iniparib BSI 56 Phase 1b clinical 56 Accelerated Partial Breast Irradiation 56 VANTAS ® 56 PROSTVAC VF 56 Vitaxin 56 MET amplification 56 lung esophageal 56 sunitinib malate 56 TNFerade ™ 56 HuMax EGFr 56 MVA MUC1 IL2 56 prospective multicenter 56 herpetic keratitis 56 pharmacokinetic PK 56 phase IIb III 56 SPIRIT III 56 carotid endarterectomy CEA 56 metastatic androgen independent 56 BR.# 56 Pivotal Study 56 Vicriviroc 56 EOquin TM phase 56 Please visit www.antisoma.com 56 samalizumab 56 velafermin 56 THALOMID 56 TroVax ® 56 LAB CGRP 56 lead Aganocide compound 56 3 registrational trial 56 oral ghrelin agonist 56 NEUVENGE 56 management biostatistical analysis 56 Coronary Artery Bypass Graft 56 Pre RELAX AHF 56 CALGB # [002] 56 include ColorectAlert TM 56 Aeolus Pharmaceuticals Announces 56 Phase 2b Trial 56 ASSERT 56 Oral Insulin Capsule 56 Viprinex TM 56 COSTAR II 56 Immunotherapeutic 56 evaluating REVLIMID 56 Phase III Trial 56 Cloretazine 56 M# rationally 56 cetrorelix pamoate 56 Phase Ia Ib 56 OMNARIS HFA 56 oral prodrug 56 postoperative mortality 56 Lung Cancer Trial 56 adjuvant colon cancer 56 HCV RESPOND 2 56 Personalized Immunotherapy 56 kidney urologic 56 Trandolapril 56 Clinical Trials Update 56 CCR5 mAb 56 OncoGel 56 PREGNANT PROCHIEVE Extending GestatioN 56 Cardio3KG 56 ABCSG 56 Diabetes ACCORD 56 Nanobody R 56 ACAPODENE 56 RELIANT Trial 56 Oncotype DX ® 56 PHASE III 56 Dose Limiting Toxicity DLT 56 stated Michelle Berrey 56 eprotirome 56 BOLDER II 56 NeuroFlo 56 MIVI TRUST 56 generation URAT1 inhibitor 56 label multicenter Phase 56 NEO3 56 Alimentary Tract 56 FOLOTYN ® 56 omacetaxine mepesuccinate 56 Syncria 56 personalized cellular immunotherapy 56 BrachySil 56 PreCISe 55 PREGNANT Study 55 CIMZIA TM certolizumab pegol 55 clinically localized prostate 55 Phase #/#a trial 55 Phase IIb trial 55 Acute MI 55 trodusquemine 55 Allovectin 7 R 55 Drug Shows Promise 55 initiate Phase Ib 55 relapsing multiple sclerosis 55 AppyScore TM 55 Tyrosine Kinase Inhibitor 55 myocardial infarction ventricular fibrillation 55 Virulizin ® 55 recurrent metastatic 55 intradialytic hypotension IDH 55 secondary efficacy endpoints 55 Aggressive Reduction 55 mSEPT9 55 By JENNIFER LEARN 55 MelaFind pivotal 55 commercialize CorMedix drug 55 GRN# 55 AA Amyloidosis 55 R lenalidomide 55 Tocosol Paclitaxel 55 severe hypercholesterolemia 55 Pivotal Phase III 55 OMP #R# 55 CAMMS# 55 Liposomal Grb 2 55 Epigenomics proprietary 55 REVIVE Diabetes 55 delivers fluocinolone acetonide FA 55 Non inferiority 55 Insegia 55 Localized Prostate Cancer 55 Commence Phase 55 please visit www.advaxis.com 55 Amigal TM 55 AP IMPACT Credibility 55 AGGRASTAT R tirofiban hydrochloride 55 LymphoStat B TM 55 Sunesis Pharma 55 SYMMETRY SM trial 55 Xcytrin R 55 Antisoma AS# 55 Pagoclone 55 tolevamer 55 Canvaxin 55 Relapsed Multiple Myeloma 55 LymphoStat B belimumab 55 initiate Phase IIb 55 DU #b 55 ChronVac C R 55 hypoxia activated prodrug 55 EMPOWER TM 55 PRoFESS 55 retinal vein occlusion induced 55 HuMax 55 Phase 1b Clinical Trial 55 systemic anaplastic large 55 INCB# [001] 55 Evaluation Program CTEP 55 prospective randomized multicenter 55 drug pipeline TAFA# 55 DAPT Study 55 recurrent glioblastoma multiforme 55 Enrolls First 55 ORACLE MS 55 DSMB recommended 55 oncolytic virus therapies 55 goserelin 55 Amrubicin 55 Phase III registrational 55 vidofludimus 55 ZACTIMA 55 Xelox 55 bavituximab monotherapy trial 55 CCX# B 55 orally inhaled migraine 55 clinical pharmacology studies 55 Spiro Rombotis President 55 MERLIN TIMI 55 Clinical Trial Results 55 PRECISE trial 55 angiographic outcomes 55 Investigational Treatment 55 initiate multicenter Phase 55 Anturol TM 55 Omacetaxine 55 Glypromate 55 Clinical Trial Data 55 randomized multicenter Phase III 55 Stereotaxis System 55 CytoFabTM 55 subcutaneous PRO 55 dose cohort 55 visceral metastases 55 GOUT 55 Xcellerated T Cells 55 lumiliximab 55 RCW breast cancer 55 Phase Ib 55 rotary VAD 55 hepatocellular carcinoma liver 55 randomized multicenter 55 PIX# [002] 55 bepotastine besilate nasal spray 55 Genz # 55 develop HBV reactivation 55 CAPRIE 55 Phase IIIb study 55 midstage clinical 55 Fibrillex TM 55 Phase IIb clinical trials 55 EndoTAG TM -1 55 Corus CAD 55 MADIT 55 ZoMaxx 55 QTinno TM 55 CALGB # [001] 55 Acute Coronary Syndromes 55 oral rivaroxaban 55 Edwards SAPIEN valve 55 TMC# [002] 55 TM Drug Eluting 55 Sipuleucel T 55 PRT# 55 agonistic human 55 Radical prostatectomy 55 Fibrin Pad 55 resminostat 55 multicenter trials 55 Phase 2a trial 55 ospemifene 55 antiangiogenic therapy 55 Presents Preclinical 55 SWOG 55 lung liver pancreas 55 EDEMA4 55 Lorianne Masuoka MD 55 via intradermal injections 55 antiretroviral naïve 55 multicenter randomized double 55 Metastatic Renal Cell Carcinoma 55 prospective multicenter randomized 55 Uterine Cancer 55 Hacksell 55 Teva Provides Update 55 Xanafide 55 Carotid Revascularization Endarterectomy vs. 55 Proxinium TM 55 Cervista HPV HR 55 Targretin capsules 55 confirmatory Phase III 55 XIENCE V demonstrated 55 Dose escalation 55 Apaziquone 55 Phase IIb 55 RELOVAIR ™ 55 Vascugel ® 55 Testosterone MDTS R 55 IND submission 55 DuraTech BioRegeneration Matrix 55 BCG refractory carcinoma 55 RESTORE CLI trial 55 Phase IIa trial 55 CBLC# 55 OncoVex 55 ARDIS 55 evaluating picoplatin 55 Trofex TM 55 paclitaxel eluting stents 55 Myocardial Infarction Study 55 SNT MC# 55 OLpur TM H2H 55 rindopepimut 55 Dr. Fahar Merchant 55 ritonavir boosted danoprevir 55 Onko Sure TM 55 vernakalant hydrochloride 55 VICTOR E1 55 Study Evaluating 55 paclitaxel Taxol R 55 Malignant Melanoma 55 angiotensin analog 55 Avastin adjuvant 55 papillary renal cell carcinoma 55 Canvaxin TM 55 MammoSite RTS 55 somatostatin analog 55 CTRC AACR San Antonio 55 Antitumor Activity 55 DIRECT Trial 55 Gastric Cancer 55 placebo controlled dose escalation 55 Subgroup Analysis 55 blood serum biomarkers 55 MOZOBIL 55 Onyx Pharmaceuticals Announces 55 Afatinib 55 Ganite ® 55 systemic Phase 1b 55 initiate Phase 2b 55 http:/www.vivus.com 55 Ketotransdel 55 receptor tyrosine kinase inhibitor 55 RSD# oral 55 Phase 2a clinical 55 confirmatory pivotal 55 label multicenter 55 SORT OUT III 55 candidate deforolimus 55 unresectable Stage III 55 TOLAMBA 55 Provectus Pharmaceuticals specializes 55 recurrent glioma 55 preclinical efficacy 55 Begins Dosing 55 hoFH 55 Panzem ® 55 RESOLUTE clinical 55 MoxDuo TM IR 55 Patient Outcomes 55 Hepatocellular Carcinoma 55 TRITON TIMI 55 AAG geldanamycin analog 55 MKC# 55 Temsirolimus 55 UroVysion 55 Syncria albiglutide 55 Nasdaq PGNX today 55 metastatic neuroendocrine tumors 55 ACTEMRA TM 55 multicentre 55 National Emphysema Treatment 55 specific CCR9 antagonist 55 DermaVir Patch 55 Syncria R 55 Ocrelizumab 55 J Antimicrob Chemother